UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 17, 2024 11:27 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel reports Second Quarter 2024 Financial Results and provides Corporate Updates
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 16, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel reports Second Quarter 2024 Financial Results and provides Corporate Updates
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
July 25, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
Sol-Gel Technologies Announces Management Realignment
July 15, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Technologies Announces Management Realignment
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
May 28, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 20, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
May 16, 2024 06:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
April 01, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
March 13, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports Full Year 2023 Financial Results and Corporate Developments
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
November 30, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
SGT-610 has “Orphan Drug” designation status in the U.S. and E.U. and “Breakthrough Therapy” designation status in the U.S., as potentially the first and only therapy aimed at preventing new BCCs in...